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Changes of 5-hydroxymethylcytosine 
distribution during myeloid and lymphoid 
differentiation of CD34+ cells
Xavier Tekpli1,11, Alfonso Urbanucci1,2, Adnan Hashim1, Cathrine B. Vågbø3, Robert Lyle4, Marianne K. Kringen5, 
Anne Cathrine Staff6, Ingunn Dybedal7, Ian G. Mills1,2,8, Arne Klungland9,10 and Judith Staerk1,7,10*
Abstract 
Background: Hematopoietic stem cell renewal and differentiation are regulated through epigenetic processes. The 
conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5hmC) by ten-eleven-translocation enzymes provides 
new insights into the epigenetic regulation of gene expression during development. Here, we studied the potential 
gene regulatory role of 5hmC during human hematopoiesis.
Results: We used reduced representation of 5-hydroxymethylcytosine profiling (RRHP) to characterize 5hmC distribu-
tion in CD34+ cells, CD4+ T cells, CD19+ B cells, CD14+ monocytes and granulocytes. In all analyzed blood cell 
types, the presence of 5hmC at gene bodies correlates positively with gene expression, and highest 5hmC levels are 
found around transcription start sites of highly expressed genes. In CD34+ cells, 5hmC primes for the expression of 
genes regulating myeloid and lymphoid lineage commitment. Throughout blood cell differentiation, intragenic 5hmC 
is maintained at genes that are highly expressed and required for acquisition of the mature blood cell phenotype. 
Moreover, in CD34+ cells, the presence of 5hmC at enhancers associates with increased binding of RUNX1 and FLI1, 
transcription factors essential for hematopoiesis.
Conclusions: Our study provides a comprehensive genome-wide overview of 5hmC distribution in human hemat-
opoietic cells and new insights into the epigenetic regulation of gene expression during human hematopoiesis.
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Background
Epigenetic regulation of gene expression plays an impor-
tant role during stem cell renewal and cell fate deter-
mination [1]. Ten-eleven-translocation (TET) DNA 
dioxygenases catalyze the hydroxylation of 5-methylcy-
tosine (5mC) into 5hmC [2]. Apart from being an inter-
mediate during the DNA demethylation process, 5hmC 
may function as a stable epigenetic mark with regulatory 
function [3], a notion supported by studies showing that 
TET enzymes and 5hmC are important for early embry-
onic development [2, 4].
Hematopoiesis, the lifelong formation of blood cells, is 
ensured by the renewal of hematopoietic stem cells and 
their differentiation into mature cell types. Mice lack-
ing TET2 are characterized by pleiotropic alterations of 
progenitor and mature hematopoietic cells, indicating 
that TET2 is an important regulator of murine blood cell 
development [5, 6]. Moreover, inactivating mutations of 
TET2 are found in various human blood disorders [7]. 
Recent studies mapping hydroxymethylated regions in 
blood cells indicated a role of 5hmC during erythropoie-
sis [8] as well as T cell and B cell differentiation [9, 10]. 
However, these reports used enrichment-based methods 
to detect 5hmC and focused on a specific lineage.
To systematically study the role of 5hmC during 
human hematopoiesis and assess the possible gene 
regulatory role of 5hmC during lymphoid and myeloid 
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differentiation, we used a single-base resolution method, 
reduced representation of 5-hydroxymethylcytosine pro-
filing (RRHP) [11]. We mapped 5hmC in CD34+ and 
mature peripheral blood cells (CD4+ T cells, CD19+ B 
cells, CD14+ monocytes and granulocytes). By integrat-
ing 5hmC profiles with gene expression analysis, histone 
modifications as well as transcription factor (TF) bind-
ing profiles we provide molecular evidence that 5hmC 
promotes the expression of key genes important for the 
differentiation of CD34+ cells into either lymphoid or 
myeloid lineage.
Results
Genome‑wide distribution and quantification of 5hmC 
in hematopoietic cells
We used RRHP analysis to quantify and assess the dis-
tribution of 5hmC-positive CCGG sites in hESC (n = 2), 
umbilical cord blood (n =  2) and bone marrow (n =  1) 
CD34+ cells (CB-CD34+ and BM-CD34+), as well as 
CD4+ T cells, CD19+ B cells, CD14+ monocytes (n = 1 
for each) and granulocytes (n  =  2) (Fig.  1a; Additional 
file 1: Table S1). We found a strong correlation in repli-
cated samples (hESC, CB-CD34+ and granulocytes) with 
Pearson’s correlation r  >  0.75 and p  <  0.05 (Additional 
file 1: Table S1). We first compared 5hmC quantification 
in the different blood cell types using RRHP (Fig. 1a) and 
liquid chromatography tandem mass spectrometry (LC/
MS/MS) (Fig. 1b). We included human embryonic stem 
cells (hESC) as reference cell type in our analysis since 
5hmC has been well characterized in those cells and it is 
known that pluripotent cells contain high levels of 5hmC 
[12, 13].
Both methods, RRHP and LC/MS/MS, showed that 
higher 5hmC levels were found in pluripotent (hESC) 
cells and multipotent (CD34+) cells compared to mature 
blood cell types (Fig. 1a, b). This was in contrast to 5mC 
levels measured by LC/MS/MS, which did not change 
between the different cell types (Additional file  2: Fig. 
S1). We next characterized the distribution of 5hmC in 
annotated elements in the different blood cell types and 
found that 78–82  % of 5hmC sites localized in introns 
and intergenic regions (Fig.  1c). Since introns and 
intergenic regions represent 80 % of the human genome, 
it was expected that most of the 5hmC sites will fall 
within these genomic elements. We therefore determined 
the relative density of 5hmC sites in annotated genomic 
elements (Fig. 1d) and found high 5hmC density in exons 
and promoter, indicating that the presence of 5hmC is 
particularly abundant around annotated genes. Notably, 
T lymphocytes showed higher 5hmC density in promot-
ers than other cell types, possibly reflecting an important 
role for 5hmC at promoters in T cells. Gene ontology 
(GO) analysis of genes with hydroxymethylated promoter 
in T cells showed a marked enrichment for biologi-
cal processes related to cell death and T cell regulation 
(p < 10−6), as well as pathways related to T cell receptor 
signaling (p < 10−4).
Taken together, we found high 5hmC density in gene 
bodies and showed that 5hmC levels decrease during cell 
differentiation.
5hmC enrichment at gene bodies positively correlates 
with gene expression
To assess the potential gene regulatory role of 5hmC dur-
ing human hematopoiesis, we integrated 5hmC profiles 
with measurement of gene expression by RNA-seq and 
genome-wide mapping of histone modifications using 
publically available ChIP-seq data sets.
We characterized 5hmC distribution around annotated 
genes. Figure 2 shows the enrichment of 5hmC −1.5-kb 
upstream of the transcription start site (TSS) to +1.5-kb 
downstream of the transcription termination site (TTS). 
We found that gene body 5hmC correlated positively 
with gene expression in all analyzed blood cell types 
(Fig.  2a–d). Specifically, when we categorized 5hmC 
enrichment 5-kb downstream the TSS, we confirmed 
that low expressed genes contained low 5hmC levels, 
while highly expressed genes showed significantly higher 
5hmC levels (Fig.  2e–h). Interestingly, 5hmC decreases 
especially at TSS of highly expressed genes [indicated by 
the blue line in the 5hmC heatmap (Fig. 2a–d)].
It is well known that repression of gene expression by 
DNA methylation mainly occurs around the TSS [14]. 
We therefore characterized 5hmC distribution around 
(See figure on next page) 
Fig. 1 5hmC levels and distribution in hematopoietic cells. a Proportion of hydroxymethylated sites in the indicated cell types. The number of 5hmC 
sites for each cell type was obtained following RRHP data analysis; n = 2 for hESC, CB-CD34+ cells and granulocytes; n = 1 for CD4+ T cells, CD19+ 
B cells and CD14+ monocytes. The mean numbers ± SEM are presented. b Quantification of 5hmC per 1 × 106 nucleotide DNA in hESC (n = 1), 
CB-CD34+ (n = 2), CD4+ T cells (n = 3), CD19+ B cells (n = 1), CD14+ monocytes (n = 3) and granulocytes (n = 3). Cells were harvested, DNA iso-
lated, hydrolyzed and analyzed for 5hmC using liquid chromatography tandem mass spectrometry (LC/MS/MS). 5hmC levels are normalized relative 
to 106 nucleosides. Data shown are the mean ± SEM. c Percentage of 5hmC in annotated genomic elements for each indicated cell type. Promoters 
were defined −1-kb upstream to +100-bp downstream of the transcription start site (TSS); transcription termination site (TTS) indicates a region 
−100-bp upstream to +1-kb downstream of the TTS. UTR untranslated region. d Relative density of 5hmC in annotated genomic elements for each 
indicated cell type. The relative density of 5hmC reflects the number of 5hmC encompassed in annotated genomic elements normalized to 105 base 
pair of the respective element and to a fixed number of 105 5hmC sites
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TSS of annotated genes (Additional file  2: Fig. S2a–d) 
and found that the TSS of high expressed genes dis-
played higher levels of 5hmC than low expressed genes. 
When we increased the resolution of our analysis around 
the TSS (±5  kb), by considering the 5hmC signal every 
50  bp (Additional file  2: Fig. S2e–h), we found that low 
expressed genes displayed a modest increase in 5hmC 
signal around the TSS, while highly expressed genes 
showed an overall higher signal characterized by a 
marked 150 bp deep around the TSS, surrounded by two 
350-bp peaks (Additional file 2: Fig. S2e–h).
Enrichment of 5hmC in the body of highly expressed 
genes also correlated with active chromatin regions 
marked by H3K4me1, H3K27ac and H3K4me3 
(Fig.  2a–d). In contrast, we observed no or an inverse 
correlation between 5hmC enrichment and regions 
containing repressive histone marks H3K27me3 and 
H3K9me3 (Fig. 2a–d). In all analyzed blood cell types, up 
to 40 and 25 % of the 5hmC were found within ChIP-seq 
peaks of active histone marks putative of poised enhanc-
ers H3K4me1 (40 %) or active enhancers H3K27ac (25 %) 
[15], while <7  % of 5hmC sites overlapped with repres-
sive histone marks H3K27me3 and H3K9me3 (Addi-
tional file 2: Fig. S3). To rule out that the association of 
5hmC with “active” histone modifications was attributed 
to an over-representation of CCGG sites within “active” 
histone ChIP-seq peaks, we compared the enrichment 
of 5hmC–CCGG to unmodified-CCGG and confirmed 
significant 5hmC enrichment in the vicinity of active his-
tone marks (Additional file 2: Fig. S3). These results dem-
onstrate that genes enriched with 5hmC are in an active 
chromatin state.
In CD34+ cells, 5hmC associates with transcription factor 
binding at enhancers
TF binding is central in the regulation of gene expression 
during hematopoiesis and is known to be affected by epi-
genetic modifications such as DNA methylation [16]. We 
therefore used publically available ChIP-seq data sets [17] 
and investigated whether the presence of 5hmC at gene 
regulatory regions could affect binding of FLI1, RUNX1, 
GATA2 and ERG, TFs crucial for blood development. 
We found that all four TFs bound chromatin enriched 
with H3K4me1, H3K27ac and H3K4me3 (Fig.  3; Addi-
tional file 2: Fig. S4), while no TF binding was detected 
in chromatin marked with H3K27me3 or H3K9me3 
(Additional file 2: Fig. S4). At putative poised enhancers 
(H3K4me1 peaks), active enhancers (H3K27ac peaks or 
dually marked H3K27ac/H3K4me1 regions), as well as 
predicted enhancers using the Hidden Markov Model 
of Ernst and Kellis: ChromHMM [18], RUNX1 and FLI1 
binding was enhanced in the presence of 5hmC (Fig. 3a–
h). The presence of 5hmC did not influence GATA2 and 
ERG binding (Fig. 3i–p).
RRHP allows us to assess 5hmC distribution in 
a CCGG-specific context [11]. Since TF binding is 
sequence specific, we ensured that increased binding of 
FLI1 and RUNX1 at enhancers positive for 5hmC was 
not biased toward the CCGG sequence. We therefore 
compared TF binding at histone modification peaks posi-
tive for CCGG and 5hmC versus histone peaks positive 
for CCGG but negative for 5hmC and confirmed a sig-
nificantly higher binding of FLI1 and RUNX1 at active 
enhancers enriched with 5hmC (Additional file  2: Fig. 
S5). Taken together, these results show that the presence 
of 5hmC in regulatory regions may increase the recruit-
ment of key hematopoietic TFs such as RUNX1 and FLI1 
at enhancers.
5hmC marks genes linked to hematopoietic differentiation
To investigate whether 5hmC marks genes linked to 
hematopoiesis in a cell-type-specific manner, we per-
formed unsupervised clustering based on gene body 
5hmC levels for all annotated genes. We identified 3208 
genes, which contained high gene body 5hmC levels in all 
analyzed hematopoietic cell types (Additional file 2: Fig. 
S6a; cluster E). Gene set enrichment analysis using GO 
and KEGG confirmed that these genes strongly associ-
ated with blood cell function (Additional file 2: Fig. S6b). 
A second unsupervised cluster analysis subdivided the 
3208 genes into six clusters (Fig.  4a; Additional file  3: 
Table S2), allowing us to identify groups of genes with 
differential gene body 5hmC levels across the mature 
blood cell types and pointing to specific 5hmC profiles 
(see figure on previous page.) 
Fig. 2 5hmC enrichment in gene bodies positively correlates with gene expression and active chromatin. Heatmaps showing the enrichment of 
the indicated epigenetic mark −1.5-kb upstream of the TSS to +1.5-kb downstream of the TTS in all annotated human genes ordered by decreas-
ing expression (log2-transformed FPKM values) in CD34+ (a), T cells (b), monocytes (c) and B cells (d). The Spearman rank (ρ) correlation coefficient 
below the heatmaps indicates the correlation between gene body 5hmC levels and gene expression (log2 FPKM) or a specific histone modification 
(exact permutation test for testing the null hypothesis of no correlation, two-tailed, *p < 5 × 10−20). Averaged 5hmC enrichment in CD34+ (e), T cells 
(f), monocytes (g) and B cells (h) 5-kb downstream of the TSS of genes expressed at high, low or intermediate level. Genes were divided into tertiles 
based on expression levels and averaged 5hmC enrichment 5-kb downstream of the TSS. Differences in 5hmC enrichment between the tertiles were 
assessed using the Kolmogorov–Smirnov test (*; #significant differences in 5hmC enrichment with D > 0.45 and p < 10−10. *High versus intermediate 
or low gene expression; #intermediate versus low gene expression)
Page 6 of 13Tekpli et al. Epigenetics & Chromatin  (2016) 9:21 
Fig. 3 In BM-CD34+ cells, 5hmC associates with increased binding of FLI1 and RUNX1. Binding of FLI1 (a, e, i), RUNX1 (b, f, j), GATA2 (c, g, h) 
and ERG (d, h, l) at regulatory elements positive (red line) or negative (blue line) for 5hmC in BM-CD34+ cells. Regulatory regions were defined by 
chromatin enrichment with a specific histone modification or the ChromHMM, chromosome segmentation and Hidden Markov Model of Ernst and 
Kellis. Putative active enhancers were defined by H3K27ac ChIP-seq peaks or H3K4me1/H3K27ac ChIP-seq peaks. Poised enhancers were defined by 
H3K4me1 ChIP-seq peaks. A specific regulatory region was considered positive for 5hmC if it contained at least one hydroxymethylated cytosine. 
Since regulatory regions throughout the genome defined by ChIP-seq peaks or ChromHMM were of different lengths, we scaled regulatory regions 
to the same length (scaled ChIP-seq peaks, x-axis) and analyzed TF occupancies (y-axis; read coverage patterns). Differences between TF enrichment 
were assessed using the Kolmogorov–Smirnov test to quantify the distance between the empirical distribution function of the TF enrichment in 
regulatory regions positive versus negative for 5hmC, *significant differences in TF occupancy with D > 0.45 and p < 10−10
(See figure on next page) 
Fig. 4 5hmC marks genes important for blood cell type function. a Using Euclidian cluster calling and the complete linkage method, 3208 genes 
(from cluster E in Additional file 2: Figure S4) were clustered according to their gene body 5hmC levels. The mean levels of gene body 5hmC from 
two biological replicates were used for granulocytes and CB-CD34+ cells. b Log2 of FPKM-averaged gene expression of all genes in the different 
clusters across the cell types. Only genes with FPKM >1 were included. Averaged log2 (FPKM) is shown ±95 % CI. *Two-tailed unpaired Student’s t 
test; p < 0.001. c Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of genes falling in the six clusters. Only the 
first two GO and KEGG terms are listed. Heat density plots showing gene-wise changes in gene expression (FPKM, y-axis) versus changes in gene 
body 5hmC (x-axis) between progenitor BM-CD34+ cells and mature blood cells: T cells (d), B cells (e) and monocytes (f). Only genes with FPKM and 
gene body 5hmC >1 were plotted. The logarithmic fold change in gene expression needed to be ≥2 to define increase or loss of gene expression in 
mature blood cells. In each plot, the Spearman rank correlation coefficient ρ and the number (n) of genes plotted are shown (exact permutation test 
for testing the null hypothesis of no correlation, two-tailed, p < 5 × 10−20)
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associated with definite blood cell function. Averaged 
expression of genes found in each cluster indicated that 
genes maintaining high gene body 5hmC levels dur-
ing differentiation of CD34+ cells into a specific mature 
blood cell type were highly expressed in the respective 
blood cell type (Fig. 4b) and recapitulated mature blood 
cell function (GO and KEGG analysis; Fig. 4c).
Such specific changes of intragenic 5hmC levels during 
CD34+ cell differentiation into a mature blood cell type 
led us to investigate how changes in gene body 5hmC lev-
els correlated with changes in gene expression. We found 
that an increase in gene expression during differentiation 
of BM-CD34+ cells into a mature cell type associated 
with the preservation or gain of gene body 5hmC levels, 
while loss of gene expression in the committed cells cor-
related with a significant decrease in gene body 5hmC 
levels (Fig.  4d–f). Similar results were obtained when 
CB-CD34+ cells were used as reference cell type (Addi-
tional file 2: Fig. S7). Taken together, our results suggest 
that in CD34+ cells, 5hmC marks key genes required for 
lineage specification and mature blood cell function.
Concomitant high gene body 5hmC levels and promoter 
DNA methylation prime genes for expression or repression 
during CD34+ cell differentiation
Our data indicated that in CD34+ cells, 5hmC primes 
genes for further expression in differentiated cells. To 
validate dynamic changes of cytosine modifications 
associated with the regulation of gene expression during 
hematopoiesis, key genes were selected from the clusters 
obtained in Fig.  4a. TNFRSF25 is a marker of activated 
T cells, CD19 a surface marker of mature B cells, while 
FOXO1 is a TF important for lymphoid lineage commit-
ment. AZU1 has been selected as a regulator of myeloid 
cell function and RUNX1 as a TF important for CD34+ 
cell homeostasis. We measured gene expression, pro-
moter DNA methylation and integrated it with gene body 
5hmC levels.
In T cells, B cells, monocytes and granulocytes, genes 
highly expressed contained significant levels of gene 
body 5hmC and low promoter DNA methylation. In 
contrast, high promoter DNA methylation and lack of 
gene body 5hmC were associated with low gene expres-
sion (Fig.  5). In CD34+ cells, DNA methylation of 
FOXO1, TNFRSF25, CD19 and AZU1 promoters was 
concomitant with high 5hmC gene body levels (Fig. 5a–
d). RUNX1, which is higher expressed in CD34+ cells, 
displayed lower promoter methylation in these cells 
(Fig.  5e). Our data indicate that in CD34+ cells, genes 
containing 5hmC and 5mC are primed for active tran-
scription in mature blood cells. During differentiation, 
loss of gene body 5hmC will result in gene repression, 
while loss of promoter DNA methylation will allow gene 
expression.
Discussion
Here, we characterized for the first time the genome-
wide distribution of 5hmC in human CD34+ progenitor 
and mature blood lineage cells. Our main findings are 
that (1) the presence of 5hmC in gene bodies positively 
correlates with gene expression and active chromatin 
state, (2) in CD34+ cells, 5hmC primes the expression of 
genes that are important for myeloid and lymphoid cell 
differentiation, and (3) in CD34+ cells, the presence of 
5hmC at enhancers may enhance binding of key hemat-
opoietic TFs.
We showed that cells with higher renewal potential 
present higher levels of 5hmC compared to differentiated 
blood cells. Importantly, differentiated blood cell types 
maintained substantial levels of 5hmC, suggesting a regu-
latory role for 5hmC rather than simply being an inter-
mediate product during the demethylation process. Gene 
expression profiles of analyzed blood cells types revealed 
that highly expressed genes display higher levels of 5hmC 
in the immediate vicinity of TSS. This is in accordance 
with recent reports [10] and clearly demonstrates that 
5hmC is found in active/open chromatin regions in 
hematopoietic cells.
Our study highlights the importance of dynamic 
changes of 5hmC distribution during CD34+ cell differ-
entiation. A recent study by Madzo et al. [8] investigated 
the role of 5hmC during in  vitro erythroid differentia-
tion and also highlighted changes of 5hmC distribution 
during erythroid cell formation. Here, we used primary 
human cells to assess 5hmC function and distribution, 
which is of great importance since it has previously been 
shown that 5hmC levels decrease quickly during in vitro 
cell culture [19]. Two recent reports studied the role of 
5hmC during mouse T and human B cell development 
into Th1/Th2 cells or plasma cells, respectively [9, 10]. 
Importantly, our study included multipotent CD34+ 
cells and mature blood cell types, which are still poorly 
studied with respect to 5hmC, and provides a valuable 
resource for a systematic analysis of 5hmC function dur-
ing the whole hematopoietic differentiation process.
Several studies, including ours, link 5hmC to histone 
modifications indicative of enhancer [20]. In addition, we 
show that in CD34+ cells, the presence of 5hmC at puta-
tive active or poised enhancers associates with increased 
binding of RUNX1 and FLI1. Whether 5hmC is depos-
ited passively in gene regulatory regions due to chro-
matin activity, or whether it functionally regulates TF 
binding and therefore gene expression remains incom-
pletely understood. Madzo et al. [8] observed a dramatic 
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decrease of 5hmC levels during erythroid differentiation 
compared to CD34+ cells, which is in agreement with 
our results. Moreover, the authors observed a strong cor-
relation between loci that gained 5hmC and binding of 
TF known to be important for erythropoiesis, support-
ing that 5hmC may be a positive regulator of TF func-
tion. In agreement with our study, these results highlight 
that 5hmC may play an important role in regulating TF 
binding affinity to their target binding sites or in priming 
chromatin-remodeling processes to allow TFs to exert 
their functions. Therefore, inactivation of TET2, which is 
known to affect blood stem/progenitor cell renewal and 
differentiation [7, 21], would lead to reduced 5hmC levels 
and may consequently lead to aberrant TF binding and 
impaired gene expression.
Recent studies suggest that 5hmC has a destabilizing 
effect on DNA structure [22, 23], while 5mC stabilizes 
chromatin [24]. In CD34+ cells, several genes showed 
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concomitant promoter DNA methylation and high gene 
body 5hmC levels. This “bivalent” 5mC/5hmC status may 
prime genes for further epigenetic regulation of their 
expression during hematopoietic development. Loss of 
gene body 5hmC would result in gene repression, while 
loss of promoter DNA methylation would allow expres-
sion. The coexistence of epigenetic marks with opposite 
effects on gene expression has previously been described 
for histone marks (H3K4me3 and H3K27me3). The 
presence of “bivalent histone domains” maps key devel-
opmental genes that need to be turned on or off during 
differentiation [25]. Importantly, 5hmC was shown to 
associate with “bivalent histone domains” in ESC [26]. 
Our analysis suggests that in CD34+ cells, gene body 
5hmC marks genes whose expression can be epige-
netically regulated during differentiation into a specific 
mature blood cell type. Taking our results in perspective 
to those of others, we find that in multipotent CD34+ 
cells, 5hmC maps genes important for lineage specifica-
tion and suggest that 5hmC may directly influence cell 
fate decisions.
Conclusions
We used a single-base resolution method to show that 
during human hematopoiesis, 5hmC accompanies exten-
sive chromatin reprogramming, including TF binding, 
and marks cell-specific genes actively transcribed in dif-
ferentiated cells that are known to be important for mye-
loid and lymphoid lineage commitment.
Methods
Human blood cells
Umbilical cord blood was collected by sterile procedure 
from healthy pregnancies. Peripheral blood was obtained 
from adult healthy donors. All subjects provided written 
informed consent. Blood cells were separated by density 
gradient, followed by cell-type-specific isolation using 
MACS MicroBeads (Miltenyi, Biotec). Bone marrow 
CD34+ cells, from a unique donor, were purchased from 
StemCell Technologies. Granulocytes, CD4+, CD19+, 
CD14+ and BM-CD34+ cells were obtained from males 
and females between 30 and 50  years old. All experi-
ments were approved by the Regional Committee for 
Medical and Health Research Ethics (2012/588/REK and 
2012/1969/REK).
Reduced representation of hydroxymethylcytosine 
profiling (RRHP)
RRHP was performed as previously described [11] by 
Zymo Research on service basis (Zymo Research, Cali-
fornia, USA). In brief, genomic DNA was fragmented 
using MspI, the sticky ends obtained were reconstituted 
using specific adapters, 5hmC was then glucosylated, 
the modified fragments were submitted to a second 
MspI digestion, and the CCGG sites with a glucosylated 
5hmC were protected from digestion and further ampli-
fied and sequenced using next-generation sequencing. 
For sequencing, equal volumes of each amplified library 
were pooled and diluted to 8  pM. Samples were six-
plexed into a single 50-bp sequencing using an Illumina 
HiSeq. FASTQ files were aligned to the human reference 
genome (hg19) with Bowtie 0.12.8 using default param-
eters and best. Only mapped sequencing reads beginning 
with a CCGG tag were considered in the analysis. The 
number of sequencing reads at a CCGG site was consid-
ered to be proportional to the level of hydroxymethyla-
tion. To compare positive 5hmC among the different cell 
types we used a more stringent read cutoff than in Pet-
terson et al. [11]. A CCGG site was considered hydroxy-
methylated if the number of sequencing reads at this site 
was >101.8 reads, which is the mean read count + SEM 
for all CCGG sites in hESC (the cell type with highest 
5hmC levels). Information regarding the RRHP data for 
each sample and replicates can be found in Additional 
file 1: Table S1.
To compare the positive 5hmC within the different 
cell types we use a more stringent read cutoff than the 
original method paper [11]. Based on our more stringent 
selection of 5hmC sites we found a strong correlation 
in replicated cell types (hESC, CB-CD34+ and granu-
locytes) with Pearson’s correlation r > 0.75 and p < 0.05 
(Additional file 1: Table S1).
Gene body 5hmC levels were determined by dividing 
the number of sequencing read at CCGG sites by the 
number of CCGG sites in the gene body.
DNA isolation and LC/MS/MS analysis
DNA from hESC (n = 1), CB-CD34+ (n = 2), as well as 
CD4+ T cells (n =  3), CD19+ B cells (n =  1), CD14+ 
monocytes (n  =  3) and granulocytes (n  =  3), was iso-
lated after proteinase K (Sigma, St. Louis, MO, USA) and 
RNase A digestion (Qiagen, Germany) followed by phe-
nol–chloroform extraction and ethanol precipitation. For 
LC/MS/MS, DNA was hydrolyzed to nucleosides by incu-
bation with nuclease P1, snake venom phosphodiesterase 
and alkaline phosphatase (Sigma-Aldrich, St. Louis, MO, 
USA). Three volumes of methanol were added after diges-
tion, and the reactions were centrifuged at 16,000g for 
30 min. The supernatants were dried under vacuum, and 
resulting residues were dissolved in 50 µl 5 % (v/v) metha-
nol for analysis. Chromatographic separation of nucleo-
sides was performed using a Shimadzu Prominence 
HPLC system with a Ascentis Express C18 150 × 2.1 mm 
i.d. (2.7 µm) reverse-phase column equipped with an 
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Ascentis Express C18 12.5 × 2.1 mm i.d. (2.7 µm) guard 
column (Agilent Technologies, USA), with a flow rate of 
0.2  ml/min at ambient temperature. The mobile phase 
consisted of A (0.1 % formic acid in water) and B (0.1 % 
formic acid in methanol), starting with 95 % A/5 % B for 
0.5 min, followed by a 6.5-min linear gradient of 5–50 % 
B, 2 min with 50 % B and 6-min re-equilibration with the 
initial mobile phase conditions. Online mass spectrom-
etry detection was performed using an AB Sciex 5000 
triple quadrupole mass spectrometer (AB Sciex, USA) 
with TurboionSpray probe operating in positive electro-
spray ionization mode. The deoxyribonucleosides were 
monitored by multiple reaction using the mass transi-
tions 228.1 → 112.1 (dC), 242.1 → 126.1 [5-me(dC)] and 
258.1 → 142.1 [5-hm(dC)].
RNA sequencing
RNA from CB-CD34+, CD4+ T cells, CD14+ mono-
cytes and CD19+ B cells was purified using the RNe-
asy Mini Kit (Qiagen). Samples with an RNA integrity 
number value >8 were used for sequencing. Libraries 
were prepared using TruSeq RNA Sample Preparation 
Kit v2 (Illumina) following the manufacturer’s instruc-
tions and sequenced with 100-bp paired-end reads on a 
HiSeq2000 Illumina. RNA-Seq data sets of BM-CD34+ 
cells (GSE63569) were downloaded from the gene expres-
sion database of Gene Expression Omnibus (GEO) [27]. 
Reads were aligned to the human reference genome 
(hg19) by TopHat v2.0.13 [28] and assembled by cuf-
flinks v2.1.1 [28] using default parameters. Quantification 
of gene expression was performed using cufflinks v2.1.1 
with default parameters to obtain fragment per kilobase 
million (FPKM) value.
Bisulfite conversion and pyrosequencing
DNA bisulfite conversion and pyrosequencing were per-
formed as previously described [29]. Primers used for 
pyrosequencing, target sequences analyzed and number 
of CpGs assessed are listed in Additional file 4: Table S3.
Analysis of publically available chromatin 
immunoprecipitation sequencing (ChIP‑seq)
Histone modification and TF-ChIP-seq data sets were 
publicly available. The accession numbers and descrip-
tion of histone modification ChIP-seq data sets are listed 
in Additional file  5: Table S4. FLI1, RUNX1, GATA2 
and ERG TF-ChIP-seq data sets [17] were downloaded 
from the gene expression database of GEO (GSE45144). 
Raw reads were aligned to the human reference genome 
(hg19) using Novoalign v2.08.02 (http://www.novocraft.
com/products/novoalign/) and default parameters. Reads 
with low quality ≤20 were removed. Chromatin enriched 
with a specific histone modification or TF binding was 
identified using MACS v1.4.1 with default parameters 
and respective input samples as background.
Prediction of active and poised enhancers
Using histone modification ChIP-seq peaks we defined 
active enhancers as regions enriched with H3K27ac, while 
putative poised enhancers were regions enriched with 
H3K4me1. We also used regions enriched with both his-
tone marks (H3K27ac and H3K4me1); here, an H3K27ac 
peak was considered to be positive for H3K4me1, if at 
least 25 % of the H3K27ac peak was covered by H3K4me1 
peaks. The H3K27ac/H3K4me1 regions were defined 
as active enhancers if they lacked TSS (TSS ±1000 bp). 
We also used the predicted enhancer region of CD34+ 
cells using the ChromHMM segmentation of Ernst and 
Kellis [18]. Predicted enhancer regions using the Hidden 
Markov Model were obtained from The NIH Roadmap 
Epigenomics Mapping Consortium.
Quantitative RT‑PCR
cDNA synthesis and qRT-PCR were performed as pre-
viously described [29]. Expression levels of target genes 
were normalized to beta-actin expression. Primer 
sequences are listed in Additional file 6: Table S5.
Statistical analyses
Student’s unpaired two-tailed t test was used to com-
pare means. In case of non-normal distribution, the 
Mann–Whitney test was used to compare medians. 
p value <0.05 was considered statistically significant. 
Hierarchical clustering was applied to log2 gene body 
5hmC levels using the Euclidean distance and complete 
linkage method. We used HOMER to perform GO and 
KEGG functional enrichment analyses, based on all Ref-
Seq genes as reference. The deepTools suite [30] and the 
computeMatrix command in scale-region mode were 
used to extract the scores of enrichment and produce 
the heatmaps of 5hmC and histone modification enrich-
ments in gene bodies. 5hmC enrichment in gene bod-
ies was obtained by normalizing RRHP-CCGG reads to 
distribution of CCGG sites in the human genome. His-
tone modification enrichment was obtained by normal-
izing ChIP-seq reads to input reads. The deepTools suite 
was used to analyze TFs occupancies (y-axis) in regula-
tory regions (scaled ChIP-seq peaks, x-axis) by normal-
izing ChIP-seq reads for RUNX1, FLI1, GATA2 or ERG 
to input reads. Kolmogorov–Smirnov test was used to 
quantify the distance between the empirical distribution 
function of two conditions.
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Availability of data and materials
The data sets supporting the conclusions of this article 
are available in the NCBI GEO (http://www.ncbi.nlm.nih.
gov/geo/) under accession number GSE69905.
Abbreviations
5mC: 5-methylcytosine; 5hmC: 5-hydroxymethylcytosine; BM: bone marrow; 
CB: cord blood; CD: cluster of differentiation; ERG: ETS-related gene; FLI1: 
friend leukemia integration 1; FPKM: fragment per kilobase million; GO: gene 
ontology; hESC: human embryonic stem cells; KEGG: Kyoto Encyclopedia of 
Genes and Genomes; RRHP: reduced representation of 5-hydroxymethylcyto-
sine profiling; RUNX1: runt-related transcription factor 1; TET: ten-eleven-trans-
location; TF: transcription factor; TSS: transcription start site; TTS: transcription 
termination site.
Authors’ contributions
XT and JS designed the original study. XT, CBV and MKK performed research. 
XT, AU and AH designed and performed bioinformatics analysis. ACS and ID 
provided essential research material. RL, IGM and AK analyzed data. XT, AU and 
JS analyzed data and drafted the manuscript. All authors read and approved 
the final manuscript.
Author details
1 Nordic European Molecular Laboratory (EMBL) Partnership, Centre for Molec-
ular Medicine Norway, University of Oslo, Blindern, P.O. Box 1137, 0318 Oslo, 
Norway. 2 Department of Molecular Oncology, Institute for Cancer Research, 
Oslo University Hospital, Oslo, Norway. 3 Department of Cancer Research 
and Molecular Medicine, Norwegian University of Science and Technology, 
Trondheim, Norway. 4 Department of Medical Genetics, University of Oslo, 
Oslo University Hospital, Oslo, Norway. 5 Department of Pharmacology, 
Oslo University Hospital, Ullevål, Oslo, Norway. 6  Department of Obstetrics 
and Gynecology, Oslo University Hospital, University of Oslo, Oslo, Norway. 
7 Department of Haematology, Oslo University Hospital, Oslo, Norway. 8 PCUK 
Movember Centre of Excellence, CCRCB, Queen’s University, Belfast, UK. 9 Clinic 
for Diagnostics and Intervention, Institute of Medical Microbiology, Oslo Uni-
versity Hospital, University of Oslo, Oslo, Norway. 10 Norwegian Center for Stem 
Cell Research, University of Oslo, Oslo, Norway. 11 Present Address: Depart-
ment of Genetics, Institute for Cancer Research, Oslo University Hospital - The 
Norwegian Radium Hospital, Oslo, Norway. 
Acknowledgements
JS is supported by the Norwegian Research Council, the Norwegian Cancer 
Society, South-East Norway Regional Health Authorities and the University of 
Oslo. We thank Lise Øhra Levy for collecting umbilical cord blood. The research 
leading to these results has received funding from the European Union 
Seventh Framework Programme (FP7-PEOPLE-2013-COFUND) under Grant 
Agreement No. 609020—Scientia Fellows. LC/MS/MS was performed by the 
Proteomics and Metabolomics Core Facility (PROMEC), Norwegian University 
of Science and Technology (NTNU), funded by the Faculty of Medicine at 
NTNU and Central Norway Regional Health Authority.
Competing interests
The authors declare that they have no competing interests.
Received: 28 February 2016   Accepted: 20 May 2016
Additional files
Additional file 1: Table S1. Summary of RRHP sequencing data. Table 
describes RRHP sequencing depth, percentage of aligned reads, raw and 
normalized 5hmC counts as well as correlation.
Additional file 2: Figure S1. Quantification of 5-methylcytosine using 
LC/MS/MS. Quantification of 5-methylcytosine (5mC) per 106 unmodi-
fied bases in hESC (n = 1), CB-CD34+ (n = 2), CD4+ T cells (n = 3), 
CD19+ B cells (n = 1), CD14+ monocytes (n = 3), and granulocytes 
(n = 3) assessed by LC/MS/MS. n indicates the number of independent 
DNA measured for each cell type. Figure S2: 5hmC at transcription start 
sites. Average enrichment of 5hmC RRHP reads (signal) along a 100 kb 
window (a-d) and 5 kb window (e–h) around the transcription start sites 
(TSS) of high and low expressed genes in the indicated hematopoietic 
cell types. Mean gene FPKM was used as threshold to dichotomize 
gene expression in high/low according to RNA-seq data in the same 
cell-types. Figure S3: 5hmC and histone modifications. Percentage of 
5hmC or CCGG sites encompassed in ChIP-seq peaks of indicated histone 
modifications. The mean percentage of 5hmC in ChIP-seq peaks from 
two independent RRHP measurements in CB-CD34+ cells and one in 
BM-CD34+ are shown ± SEM. The mean percentages of CCGG sites found 
in ChIP-seq peaks of CD34, T cell, monocyte and B cell are shown.*** or 
* indicate significant difference between CCGG distribution in ChIP-seq 
peaks versus 5hmC distribution in ChIP-seq peaks of hematopoietic cells. 
*** p < 0.0001, * p < 0.05; Student’s unpaired two tailed t-test. Figure 
S4: 5hmC and transcription factor occupancy at inactive chromatin. 
FLI1, RUNX1, GATA2 and ERG occupancies at putative active promoters 
(H3K4me3 peaks), putative inactive chromatin enriched with H3K27me3 
or H3K9me3. A specific ChIP-seq peak was considered positive for 5hmC 
when it contained at least one hydroxymethylated cytosine. In histone 
modification ChIP-seq-peaks positive or negative for 5hmC we assessed 
how TF-ChIP-seq reads were distributed which reflected the level of 
occupancy of an inactive chromatin region by a TF. The diagrams show 
the occupancy of a TF in inactive chromatin positive (red line) or nega-
tive (blue line) for 5hmC. Figure S5: Transcription factor occupancy at 
putative regulatory elements. FLI1, RUNX1, GATA2, ERG occupancies at 
regulatory elements in BM-CD34+ cells. Regulatory regions were defined 
by chromatin enrichment with histone modifications: H3K4me1 or 
H3K27ac-ChIP-seq peaks defined putative active enhancers, H3K4me3-
ChIP-seq peaks defined active promoter regions. A specific regulatory 
region was considered positive for 5hmC if it contained at least one 5hmC 
site. In histone modification ChIP-seq-peaks we assessed how particular 
transcription factor ChIP-seq reads were distributed, which is proportional 
to binding. Occupancy of the indicated transcription factors in regulatory 
elements containing 5hmC-positive CCGG (red line) or 5hmC-negative 
CCGG (blue line) sites are shown. Enrichment of TFs (y-axis) at regulatory 
regions (scaled ChIP-seq peaks, x-axis). Differences between TF enrich-
ment were assessed using the Kolmogorov–Smirnov test to quantify the 
distance between the empirical distribution function of the TF enrich-
ment in regulatory regions positive versus negative for 5hmC, * indicates 
significant differences in TF occupancy with D > 0.3 and p < 5.10-4. Figure 
S6: Changes in 5hmC gene body levels. a: Heat map representation of 
all known human genes clustered according to their gene body 5hmC 
levels. Euclidian cluster calling was used to produce the heat map. The five 
clusters identified are labeled with a letter and the number of genes per 
cluster is indicated. The mean levels of gene body 5hmC from two biologi-
cal replicates were used for granulocytes and CB-CD34+ cells. b: Gene 
ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
analyses of genes identified in the five clusters in panel A. The first two 
GO and KEGG terms are listed. Figure S7: Changes in 5hmC gene body 
levels versus changes in expression. Heat density plots depict the changes 
in gene expression (FPKM, y axis) versus changes in gene body 5hmC (x 
axis) from progenitor cells (CB-CD34+ cells) to mature blood cells: T cells 
(a), B cells (b) and monocytes (c). Only genes with FPKM and gene body 
5hmC > 1 were plotted. The logarithmic fold change in gene expression 
needed to be > 2 to define gain or < 2 to define loss of gene expression. 
In each plot, the Spearman rank correlation coefficient ρ and the number 
(n) of genes plotted are shown (exact permutation test for testing the null 
hypothesis of no correlation, two tailed, p < 5 × 10−20).
Additional file 3: Table S2. Gene list described in Fig. 4a.
Additional file 4: Table S3. Primer used in pyrosequencing and coordi-
nates of DNA sequence analyzed.
Additional file 5: Table S4. Publically available histone ChIP-seq data 
sets used.
Additional file 6: Table S5. Primers used in qRT-PCR.
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